HMGB2 depletion enhances NK cell cytotoxicity via the ANGPT1/PI3K/AKT pathway, suggesting its potential as a therapeutic target to improve NK cell-based immunotherapy in ESCC. The gene discussed is ANGPT1; the disease is esophageal squamous cell carcinoma.